Abstract:Background: Since their discovery in 1928, antibiotics have revolutionized modern human medicine. A direct consequence of their widespread use and abuse is the concomitant development of sophisticated resistance mechanisms by microbes to most of these antibiotic agents. With a sharp fall in the number of new antibiotic agents under development, due to a decline in sectoral investment by the major pharmaceutical firms, now more than ever, there is an urgent need for alternative antimicrobial agents, to overcome the global health crisis of antimicrobial resistance. One such alternative are the CRISPR-Cas systems. In this review, we discuss the discovery and evolution of the CRSIPR-Cas system, their classification, their application as antimicrobial agents and the current limitations to their use. Main Body: Since their discovery in 1987, the CRISPR-Cas systems have evolved to possess several applications in biomedical science, including their use in gene editing, genome engineering and for treating genetic diseases. One potential application that has received less attention however is their use as sequence-specific antimicrobials. The three steps in their mechanism of action – spacer acquisition, biogenesis and interference, have been demonstrated to be effective for the highly-specific elimination of targeted bacterial strains from a mixed population of bacteria in a microbial community, as well as for driving a positive selection pressure for the development of antibiotic-sensitive bacterial strains, even to the point of reversing antimicrobial resistance through the elimination of the resistance genes. However, the use of CRISPR-based antimicrobials is fraught with several challenges, ranging from concerns about delivery platforms (phage-based vs. conjugative plasmids), their application on complex microbial communities, safety considerations, to the possibility of resistance and the many regulatory hurdles against their widespread use. Conclusion: While their efficacy has been confirmed, more studies are required to further establish CRISPR-Cas based antimicrobials in conventional medical practice.

Advances in CRISPR-Cas systems for human bacterial disease

Survival and Evolution of CRISPR-Cas System in Prokaryotes and Its Applications.

The CRISPR/Cas system: Gene Editing by bacterial defense

The CRISPR-Cas system: its origin, functions and applications in biotechnology: A Review

Development of clustered regularly interspaced short palindromic repeats/CRISPR-associated technology for potential clinical applications

Endogenous CRISPR-Cas System-Based Genome Editing and Antimicrobials: Review and Prospects

An overview and potential of CRISPR-Cas systems for genome editing

CRISPR-Cas Systems Target Endogenous Genes to Impact Bacterial Physiology and Alter Mammalian Immune Responses.

Using CRISPR-Cas systems as antimicrobials

CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance

CRISPR-Cas for genome editing: Classification, mechanism, designing and applications

Recent advances of the biological and biomedical applications of CRISPR/Cas systems

CRISPR-based strategies in infectious disease diagnosis and therapy

CRISPR-Cas System: The Current and Emerging Translational Landscape

CRISPR-Cas: biology, mechanisms and relevance

Novel CRISPR–Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives

CRISPR-Cas Systems: Programmable Nuclease Revolutionizing the Molecular Diagnosis

Advances in CRISPR-Cas systems for gut microbiome

CRISPR-Cas Systems: A Review of their Role as Non-Canonical Antimicrobials to Combat Drug Resistance

Evolution of CRISPR/Cas Systems for Precise Genome Editing

CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria